Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab in Recurrent Glioblastoma
NCT06672575Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2025
- Primary completion
- Jan 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ivonescimab in glioblastoma (GBM), sponsored by University of Texas MD Anderson Cancer Center. Started Jan 2025; status: recruiting.
02
Drugs
ivonescimab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT06672575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06672575.